Syntheses and evaluation of new Quinoline derivatives for inhibition of hnRNP K in regulating oncogene c-myc transcription
作者:Bing Shu、Ping Zeng、Shuangshuang Kang、Peng-Hui Li、Dexuan Hu、Guotao Kuang、Jiaojiao Cao、Xiaoya Li、Meiling Zhang、Lin-Kun An、Zhi-Shu Huang、Ding Li
DOI:10.1016/j.bioorg.2018.12.020
日期:2019.4
Therefore, down-regulation of c-myc transcription by inhibiting hnRNP K through disrupting its binding to c-myc gene promoter is a potential approach for cancer therapy. In the present study, we synthesized and screened a series of Quinoline derivatives and evaluated their binding affinity for hnRNP K. Among these derivatives, (E)-1-(4-methoxyphenyl)-3-(4-morpholino-6-nitroquinolin-2-yl)prop-2-en-1-one (compound
异质核糖核蛋白K(hnRNP K)的异常过表达是许多人类癌症的发生和发展的关键特征。已发现hnRNP K是上调c-myc基因转录的转录激活因子,c-myc基因转录是调节细胞生长和分化的关键原癌基因。因此,通过破坏hnRNP K破坏其与c-myc基因启动子的结合来抑制c-myc转录是癌症治疗的一种潜在方法。在本研究中,我们合成并筛选了一系列喹啉衍生物,并评估了它们对hnRNP K的结合亲和力。在这些衍生物中,(E)-1-(4-甲氧基苯基)-3-(4-吗啉代-6-硝基喹啉-确定2-(基)丙-2-烯-1-酮(化合物25)是第一个报告的hnRNP K结合配体,其KD值为4.6和2。用SPR和MST分别测得6μM。随后的评估表明,化合物25与hnRNP K的结合可破坏其c-myc启动子i-motif的展开,从而导致c-myc转录的下调。化合物25对人癌细胞系表现出选择性的抗增殖作用,IC50值为1.36至3